Suchergebnisse - "Hasselbalch, Hans Carl"

PubPharm (9)

1

Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis : a phase II study

enthalten in: Haematologica | 2020

von Sørensen, A. | Mikkelsen, S. | Knudsen, T. | +17

CommentIn: Haematologica. 2020 Jun 05;105(9):2190-2191. - PMID 33054041

2

Ruxolitinib treatment reduces monocytic superoxide radical formation without affecting hydrogen peroxide formation or systemic oxidative nucleoside damage in myelofibrosis

enthalten in: Leukemia & lymphoma | 2019

von Bjørn, M. | Brimnes, M. | Gudbrandsdottir, S. | +5

3

Safety and efficacy of combination therapy of interferon-α2 and ruxolitinib in polycythemia vera and myelofibrosis

enthalten in: Cancer medicine | 2018

von Mikkelsen, S. | Kjaer, L. | Bjørn, M. | +14

4

Philadelphia chromosome-negative classical myeloproliferative neoplasms : revised management recommendations from European LeukemiaNet

enthalten in: Leukemia | 2018

von Barbui, T. | Tefferi, A. | Vannucchi, A. | +20

5

Minimal residual disease or cure in MPNs? Rationales and perspectives on combination therapy with interferon-alpha2 and ruxolitinib

enthalten in: Expert review of hematology | 2017

von Bjørn, M. | Hasselbalch, H.

6

Ruxolitinib is manageable in patients with myelofibrosis and severe thrombocytopenia : a report on 12 Danish patients

enthalten in: Leukemia & lymphoma | 2016

von Bjørn, M. | Holmström, M. | Hasselbalch, H.

7

Fibroproliferative activity in patients with immune thrombocytopenia (ITP) treated with thrombopoietic agents

enthalten in: British journal of haematology | 2011

von Ghanima, W. | Junker, P. | Hasselbalch, H. | +6

8

New treatment options for primary immune thrombocytopenia

enthalten in: Ugeskrift for laeger | 2011

von Gudbrandsdottir, S. | Frederiksen, H. | Birgens, H. | +4

9

Novel medical treatment modalities in hematology

enthalten in: Ugeskrift for laeger | 2008

von Hasselbalch, H. | Birgens, H. | Dufva, I. | +4

1
[1]